In the past few years selective BRAF inhibitors, such as vemurafenib and dabrafenib have been approved by FDA and EMEA for the treatment of metastatic melanomas harbouring V600E mutant BRAF.6, 7 Although BRAF inhibitors produce clinical responses, e.g., improvement of progression free survival and overall survival in patients with mutant BRAF melanoma, the associated effects are short-lived. This evidence concerns the gene BRAF and metastatic melanoma.